What is Veriskin?
Veriskin is a medical technology innovator focused on transforming skin cancer detection through its flagship TruScore device. By leveraging advanced artificial intelligence, the company provides front-line care providers with a handheld, non-invasive tool capable of delivering real-time, dynamic assessments of suspect skin growths in under two minutes. This technological advancement addresses a significant gap in early-stage diagnostic accuracy, positioning Veriskin as a pivotal player in the digital health and oncology screening sectors. The company's commitment to rapid, reliable results empowers clinicians to make informed decisions at the point of care, effectively streamlining the patient triage process.
How much funding has Veriskin raised?
Veriskin has raised a total of $1M across 1 funding round:
Angel/Seed
$1M
Angel/Seed (2021): $1M with participation from Frontier Angels, Ariel Savannah Angel Partners, Pasadena Angels, and TiE SoCal Angels
Key Investors in Veriskin
Frontier Angels
A Montana-based network of accredited investors dedicated to accelerating early-stage technology startups through capital and strategic guidance.
Pasadena Angels
A non-profit organization established in 2000 that provides essential early-stage funding and mentorship to high-potential ventures in the Los Angeles region.
Ariel Savannah Angel Partners
Undisclosed investor participating in the funding round.
What's next for Veriskin?
With this major enterprise-level funding, Veriskin is well-positioned to accelerate its commercialization strategy and expand its footprint within the global healthcare market. The strategic roadmap likely includes scaling manufacturing capabilities for the TruScore device, pursuing additional regulatory clearances, and deepening its integration into existing electronic health record systems. By focusing on operational efficiency and clinical validation, Veriskin aims to solidify its market leadership, ensuring that its AI-driven diagnostic tools become a standard component of dermatological screening protocols worldwide.
See full Veriskin company page
